Commercialization of Human Visceral Adipocytes

Information

  • Research Project
  • 6689059
  • ApplicationId
    6689059
  • Core Project Number
    R43DK065323
  • Full Project Number
    1R43DK065323-01
  • Serial Number
    65323
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/2003 - 21 years ago
  • Project End Date
    2/28/2004 - 21 years ago
  • Program Officer Name
    KUCZMARSKI, ROBERT J.
  • Budget Start Date
    9/1/2003 - 21 years ago
  • Budget End Date
    2/28/2004 - 21 years ago
  • Fiscal Year
    2003
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/1/2003 - 21 years ago
Organizations

Commercialization of Human Visceral Adipocytes

DESCRIPTION (provided by applicant): The US is experiencing an epidemic rise in obesity [1] and related co-morbidities, such as type 2 diabetes. Epidemiological studies demonstrate that these co-morbidities are specifically correlated with visceral (intra-abdominal) fat deposition. To elucidate this association, an ideal model, human visceral adipocytes, must be made available to researchers. Zen-Bio, Inc. will address this need by developing a characterized, commercially accessible source of cultured human visceral preadipocytes. Preliminary data indicate that visceral preadipocytes are distinct from subcutaneous adipocytes, requiring individualized culturing techniques. Aim 1 of this proposal will seek to maximize visceral preadipocyte recovery from small solid tissue samples by improving mechanical and enzymatic dissolution of tissue and removal of contaminating cell types. Aim 2 will focus on expansion of the visceral preadipocytes to at least 20 million cells by developing growth factor cocktails and determining optimal seeding densities. Aim 3 will assess two parameters, advanced age of a donor or increased time post-mortem, for negative impact on total cell recovery, viability and/or growth characteristics. This Phase I SBIR concentrates on developing specialized techniques needed for culture of visceral preadipocytes. In Phase II we will focus on differentiating these cells into mature visceral adipocytes, followed by optimization of cell-based assays to effectively utilize these cells.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ZEN-BIO, INC.
  • Organization Department
  • Organization DUNS
    799863261
  • Organization City
    RTP
  • Organization State
    NC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    27709
  • Organization District
    UNITED STATES